Resources

If you need more information feel free to contact our Help Center

Featured

Drug discovery has been missing decision-quality evidence. Causaly is working with Microsoft to close the gap.

In this domain, decision quality depends not only on generating answers quickly, but on being able to explain why the answer is credible, what supports it, what contradicts it, and what to do next.

June 2, 2026
Read more
BlogNewsEvents & WebinarsCase studiesDownloads

Blog

Discover the latest reports, data sheets, articles, infographics, and videos on biomedical R&D and AI.

causaly
Disease Pathophysiology
Target selection
Safety
Biomarkers

Why Enterprise AI Needs More Than Coding Agents in Life Sciences

Yiannis Kiachopoulos
June 2, 2026

The conditions that make AI coding feel effortless are mostly absent in biomedical science. That gap defines what enterprise R&D leaders should build for.

Read more

Drug discovery has been missing decision-quality evidence. Causaly is working with Microsoft to close the gap.

June 2, 2026

In this domain, decision quality depends not only on generating answers quickly, but on being able to explain why the answer is credible, what supports it, what contradicts it, and what to do next.

Read more

Introducing Scientific Workflows: Turn Scientific Expertise into Scalable Execution

Yiannis Kiachopoulos
May 28, 2026

Causaly Scientific Workflows codifies expert research processes into governed, repeatable, end-to-end agentic automations that produce structured, evidence-backed outputs at key decision points in the R&D pipeline.

Read more

What Makes an Agentic Workflow Decision-Ready?

Written by Stavroula Ntoufa and Ramon Perez
May 19, 2026

Decision-readiness depends on whether an output takes a position, surfaces the contradictions that matter, and names the gaps that would change the conclusion, not on how much evidence it contains.

Read more

Scientific Workflows as Organizational Memory: How Pharma Encodes What Its Best Scientists Know

Written by Stavroula Ntoufa and Ramon Perez
May 11, 2026

A well-designed scientific workflow does something documentation cannot.

Read more

Why SOPs are not enough to run scientific workflows

Team Causaly
April 28, 2026

The gap between a documented SOP and an executable workflow is a gap in design, not in effort or rigour.

Read more

Unraveling Mechanisms of Disease Pathogenesis with AI

Anna Tzani
March 6, 2024

AI-supported investigations into disease mechanisms offer a transformative approach to understand complex pathologies. By leveraging AI to unlock disease understanding, researchers can identify novel biomarkers and therapeutic targets with unprecedented precision. This not only accelerates the journey from lab to market but also enhances the efficacy and safety of new treatments.

Read more

Leveraging AI for Scientific Knowledge Extraction

Anna Tzani
February 13, 2024

AI is transforming the analysis of extensive biomedical data, allowing pharma companies to expedite R&D processes, and cut costs. By reaching conclusions quicker, the inclusion of AI in drug development pipelines can inform decision-making, enabling the prioritization of more promising research avenues.

Read more

Exploring the Disease Pathophysiology of Rheumatoid Arthritis

Anna Tzani
February 6, 2024

Understanding the pathophysiology of a disease is pivotal in comprehending its cause and progression and facilitating the identification of novel targets for therapeutic intervention. Data-driven strategies are essential in navigating this complexity, facilitating a deeper understanding of disease pathophysiology, which can be leveraged to develop more effective treatments.

Read more

Search by Target Class: Enzyme Targets for Celiac Disease

Anna Tzani
January 26, 2024

The strategic prioritization of drug targets by target class can be used to streamline discovery, enabling efficient resource allocation and time-savings in early drug development, as well as a competitive edge given the variable success rates of different target classes. Prioritization of specific target classes may therefore enable investment optimization in preclinical research.

Read more

Navigating the Biomedical Literature: Insights vs. Papers

Anna Tzani
January 19, 2024

With 2 publications added to PubMed every minute, identifying therapeutic targets with traditional keyword searching is time-consuming, causes reading fatigue and is subject to bias. By machine-reading the literature, Causaly manages this data overload, extracting scientific insights rather than papers, to enable the exploration of more novel avenues.

Read more

Uncovering the Mechanism of Action of Evolocumab against PAD

Anna Tzani
January 12, 2024

Deciphering a drug’s MoA is crucial for making informed decisions in drug development, paving the way for the development of more targeted and effective therapeutic solutions. AI can revolutionize this process by facilitating knowledge discovery without bias, unveiling hidden drug-disease interactions.

Read more

How Manas AI uses Causaly to validate targets and reduce early-stage risk

Team Causaly
March 26, 2026

In this conversation, Dr. Siddhartha Mukherjee (Manas AI) and Yiannis Kiachopoulos (Causaly) examine how AI is being applied across this entire pipeline, not as a single model, but as a system of interconnected decisions.

Read more

ProQR Uses Causaly to Support Target Identification For Axiomer™ Platform

Yiannis Kiachopoulos
January 28, 2025

ProQR faced challenges with bandwidth, aggressive targets, and the overwhelming growth of biomedical literature. Causaly's AI platform accelerated ProQR’s R&D by enabling faster review of publications and allowing their team to make more informed decisions. Read the case study below to learn how ProQR met their 2024 target ID goal by Q3 and achieved 5x productivity compared to using PubMed.

Read more

Enhance Your Search Sensitivity with AI: Off-Target Effects of BRAF

Anna Tzani
February 29, 2024

In contrast to conventional keyword searching techniques, Causaly’s AI can sift through and remove irrelevant data from biomedical searches, offering a more thorough and accurate understanding of entire research landscapes. This not only streamlines knowledge acquisition but ensures accuracy and precision in navigating the biomedical literature.

Read more

Leveraging AI for Scientific Knowledge Extraction

Anna Tzani
February 13, 2024

AI is transforming the analysis of extensive biomedical data, allowing pharma companies to expedite R&D processes, and cut costs. By reaching conclusions quicker, the inclusion of AI in drug development pipelines can inform decision-making, enabling the prioritization of more promising research avenues.

Read more

Search by Target Class: Enzyme Targets for Celiac Disease

Anna Tzani
January 26, 2024

The strategic prioritization of drug targets by target class can be used to streamline discovery, enabling efficient resource allocation and time-savings in early drug development, as well as a competitive edge given the variable success rates of different target classes. Prioritization of specific target classes may therefore enable investment optimization in preclinical research.

Read more

Navigating the Biomedical Literature: Insights vs. Papers

Anna Tzani
January 19, 2024

With 2 publications added to PubMed every minute, identifying therapeutic targets with traditional keyword searching is time-consuming, causes reading fatigue and is subject to bias. By machine-reading the literature, Causaly manages this data overload, extracting scientific insights rather than papers, to enable the exploration of more novel avenues.

Read more

Aiding Drug Repurposing Investigations with AI

Anna Tzani
February 23, 2024

Drug repurposing offers a cost-effective and efficient pathway to discovery new therapeutic uses for existing treatments. AI can advance this process by rapidly analyzing large-scale biomedical data and scientific texts to identify drug-disease relationships, opening up avenues for treatments in unexplored indications.

Read more

Comparison of Safety Biomarkers for Chemotherapeutics

Anna Tzani
February 9, 2024

The identification and utilization of safety biomarkers plays a key role in mitigating toxicity risks and reducing costs in drug development, thereby accelerating the delivery of safe and effective drugs to patients. AI can streamline the identification of relevant biomarkers from the ever-growing biomedical literature, offering insights into drug resistance and toxicity.

Read more

AI-Powered Drug Discovery: Identifying Safety Red Flags

Anna Tzani
January 30, 2024

Unmanageable toxicity accounts for 30% of clinical drug development failures and can cause severe side effects and potential harm to patients. Download our report to see how AI-powered drug discovery can help mitigate late-stage clinical failures and market withdrawals.

Read more

Comparison of Safety Biomarkers for Chemotherapeutics

Anna Tzani
February 9, 2024

The identification and utilization of safety biomarkers plays a key role in mitigating toxicity risks and reducing costs in drug development, thereby accelerating the delivery of safe and effective drugs to patients. AI can streamline the identification of relevant biomarkers from the ever-growing biomedical literature, offering insights into drug resistance and toxicity.

Read more

Challenging the Status Quo: A Biomarker Use Case

Anna Tzani
January 24, 2024

Traditional keyword searching is highly inefficient, subject to bias and is not always comprehensive, providing limited potential for knowledge discovery and hypothesis generation. This selective approach introduces a bias towards familiar areas of expertise, which can lead to missed opportunities for novel insights and innovations. This is where AI comes in.

Read more

Biomarkers of Treatment Response in Liver Cancer

Anna Tzani
December 7, 2023

Biomarkers serve as objective measures of treatment response to guide patients towards the most appropriate therapies. Yet, in the era of big data, pinpointing promising biomarkers remains a challenging endeavor. AI is revolutionizing translational medicine by improving the efficiency and accuracy of biomarker identification.

Read more

Expedite Biomarker Discovery with Human-Centric AI

Anna Tzani
December 4, 2023

Biomarkers are pivotal throughout drug development, from discovery to market, playing key roles in unravelling drug mechanisms, providing prognostic insights and assessing treatment efficacy. Despite the clinical promise, biomarker development is challenging. There are substantial obstacles, from disease heterogeneity and rigorous validation requirements to the inability to extract meaningful biomarker insights from extensive biological data.

Read more
Read more

News

The latest news and updates from Causaly.

news

Causaly and Microsoft Collaborate to Connect Scientific Computation to Scientific Decision-Making for Life Sciences R&D

June 2, 2026

Helping R&D teams move from raw internal data to cited, defensible scientific decisions in a single governed workflow —setting a new standard for speed, rigor, and provenance in drug discovery and development

Read more
news

Causaly Introduces Scientific Workflows to Turn Expert Scientific Methods into Repeatable, AI-Executed Processes in Life Sciences

Team Causaly
May 28, 2026

Causaly platform codifies biopharma R&D processes into end-to-end workflows that AI agents run consistently for any program, team, and therapeutic area

Read more
news

The Medicine Maker: Why Copilots Failed in R&D and What Comes Next

As featured in The Medicine Maker
March 30, 2026

Organizations that benefit most from AI in R&D will be those that align technology with scientific reality

Read more
news

How Agentic AI Learns to Think Like a Scientist

January 14, 2026

What happens when AI stops guessing and starts reasoning? Agentic AI is bringing scientific logic into the heart of drug discovery.

Read more
news

Causaly Launches Agentic AI Platform to Transform Life Sciences R&D

Team Causaly
October 9, 2025

Causaly has unveiled Causaly Agentic Research, a breakthrough agentic AI platform purpose-built for life sciences research and development.

Read more
news

Causaly Introduces First Agentic AI Platform Built for Life Sciences Research and Development

Team Causaly
September 16, 2025

Specialized AI agents automate research workflows and accelerate drug discovery and development with transparent, evidence-backed insights

Read more
Read more

Events and Webinars

Our events and webinars on demand and dig deeper into the next era of scientific research.

Webinar

Automate Your Research Workflows - From Question to Confident Decision

No items found.
June 17, 2026

Join us for an exclusive look at Scientific Workflows by Causaly. The governed agentic automation solution moving life sciences R&D from scientific intelligence to scientific execution.

Watch now
Webinar

Causaly Dissected: Accelerating Medical Affairs with Agentic AI Research

June 10, 2026

About the series: Causaly Dissected is our monthly live demo series. Each 30-minute episode takes one life sciences use case and pulls it apart in real time. The workflow mirrors the use cases staring with a scientific question, and running through all the critical next steps including the agentic research run, the cited evidence, and the deliverable a working scientist would actually hand to a colleague.

Watch now
Webinar

Agentic AI and the New Pace of Drug Discovery

March 12, 2026

Join Manas AI co-Founder, CEO and distinguished author Dr. Siddhartha Mukherjee, alongside Causaly CEO and Co-Founder Yiannis Kiachopoulos, for a gripping discussion exploring how AI is can carry out scientific reasoning in R&D.

Watch now
Webinar

Autonomous AI Agents for Life Sciences R&D

No items found.
October 15, 2025

In this exclusive webinar, we showcased Agentic Research by Causaly. Our groundbreaking technology that redefines R&D processes with the implementation of autonomous AI research agents.

Watch now
Webinar

The Business Case for AI with Novartis and Gartner

No items found.
August 14, 2025

In this webinar, experts from Gartner and Novartis join the Causaly team to share their insights into the latest AI technologies transforming life sciences, and how to put those AI tools to work in real world pharma use cases.

Watch now
Webinar

Bring Competitive Intelligence to your Scientific Research

No items found.
June 24, 2025

Join us for an exclusive webinar where we’ll showcase Causaly's Pipeline Graph, our latest AI-powered application that brings competitive insights upstream to compare programs, de-risk early decisions, and optimize R&D investment.

Watch now
Read more

Case studies

Read our latest case studies and see how we’ve helped our customers.

Case studies

How Causaly Cut Proposal Time by 75% During a Critical Disease Area Transition

Top 10 Global Life Sciences Company
April 30, 2026
Read more
Case studies

How a Top 10 Pharma Company Transformed Clinical Program Evaluation with Causaly

Top 10 Pharma
March 25, 2026
Read more
Case studies

How a scientist accelerates target validation with Causaly

Top 50 Pharma
February 20, 2026
Read more
Case studies

Using Causaly to Accelerate Clinical Evidence Validation for FDA Submissions

Top 50 Pharma
January 7, 2026
Read more
Case studies

How Innate Pharma uses Causaly for systematic target identification

Innate Pharma
December 8, 2025
Read more
Case studies

Unlocking new therapeutic horizons: How researchers accelerate drug repurposing with Causaly

Top 20 Pharma
November 14, 2025
Read more
Read more

Downloads

The latest downloadable content from Causaly.

Download

Benchmarking Agentic AI for Life Sciences

December 4, 2025
Read more
Download

Scientific Information Retrieval System: The Foundation of Causaly’s Agentic AI Platform

November 24, 2025
Read more
Download

Target Discovery Factsheet: Navigate the Target Landscape of Prostate Cancer

January 29, 2025
Read more
Download

Spotlight On Biomarkers Uncover the Latest Biomarkers of Disease Progression, Prediction and Survival

November 15, 2024
Read more
Download

Infographic: Target Discovery in Endocrinology

October 23, 2024
Read more
Read more
Causaly logo

Unlock scientific insights from external and internal information at unprecedented levels of precision and efficiency.

Get started
Login
Causaly
AboutRequest a demoContact usResourcesCareers
LEGAL
Privacy policy
Terms of service
Cookies settings
© Causaly. All rights reserved.